Trial reportPloS one2015
Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial.
Trial report in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00774462 (FORCE), which is not on this map. Cited by 59 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis
Who cites it
59 citing papers in PubMed, 5 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.The European respiratory journal · 2026Guideline
- Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.Respiratory research · 2022Pooled it
- Defining anti-synthetase syndrome: a systematic literature review.Clinical and experimental rheumatology · 2022Pooled it
- Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Abatacept for the treatment of myositis-associated interstitial lung disease.Rheumatology (Oxford, England) · 2025Trial
- Clinical characteristics of anti-Ro52/TRIM21-positive versus anti-Ro52/TRIM21-negative patients with anti-synthetase syndrome: a retrospective cohort study.Clinical rheumatology · 2026Article
- Emerging therapies in idiopathic inflammatory myopathies.Journal of neuromuscular diseases · 2026Review
- Article
- Rituximab in Connective Tissue Disease-Associated Interstitial Lung Disease: From Immunopathogenesis to Therapeutic Implications.International journal of molecular sciences · 2025Review
- A case of anti-EJ anti-synthetase syndrome (EJ-ASS) with anti-Ro-52 overlap presenting with progressive interstitial lung disease (ILD) with subtle myopathy - A case report and literature review.Clinical rheumatology · 2025Review
- Tacrolimus as first-line therapy in a US cohort of idiopathic inflammatory myopathies related interstitial lung disease.Rheumatology (Oxford, England) · 2025Article
- Predictive Biomarkers and Novel Treatments for the Progressive Fibrosing Phenotype in Interstitial Lung Disease Associated with Connective Tissue Disease.Biomedicines · 2025Review
- Case Report: Telitacicept for interstitial lung disease associated with idiopathic inflammatory myopathies: an observational study.Frontiers in pharmacology · 2025Article
- Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review.Frontiers in medicine · 2025Review
- Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort.Clinical rheumatology · 2024Article
- ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4 + T cells into Th17 and Treg subsets.Skeletal muscle · 2024Article
- A Review of Myositis-Associated Interstitial Lung Disease.Journal of clinical medicine · 2024Review
- Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome.Arthritis research & therapy · 2024Observational
- Novel Therapeutic Approaches in Connective Tissue Disease-Associated Interstitial Lung Disease.Seminars in respiratory and critical care medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAnti-synthetase syndrome (anti-SS) is frequently associated with myositis and interstitial lung disease (ILD). We evaluated prospectively, in a multicenter, open-label, phase II study, the efficacy of rituximab on muscle and lung outcomes.
methodsPatients were enrolled if they were refractory to conventional treatments (prednisone and at least 2 immunosuppressants). They received 1 g of rituximab at D0, D15, and M6. The primary endpoint was muscular improvement based on manual muscular testing (MMT10, Kendall score in 10 muscles) at M12. Secondary endpoints were normalization of creatine kinase (CK) level, ILD improvement based on forced vital capacity and/or diffuse capacity for carbon monoxide, and number and/or doses of associated immunosuppressants.
resultsTwelve patients were enrolled, and 10 completed the study. Only 2 patients presented an improvement of at least 4 points on at least two muscle groups (primary end-point). Overall, seven patients had an increase of at least 4 points on MMT10. CK level decreased from 399 IU/L (range, 48-11,718) to 74.5 IU/L (range, 40-47,857). Corticosteroid doses decreased from 52.5 mg/d (range, 10-70) to 9 mg/d (range, 7-65) and six patients had a decrease in the burden of their associated immunosuppressants. At baseline, all 10 patients presented with ILD. At M12, improvement of ILD was observed in 5 out of the 10 patients, stabilization in 4, and worsening in 1.
conclusionsThis pilot study of rituximab treatment in patients with refractory anti-SS provided data on evolution of muscular and pulmonary parameters. Rituximab should now be evaluated in a larger, controlled study for this homogenous group of patients.
trial registrationClinicaltrials.gov NCT00774462.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.